Back to top
more

Surmodics (SRDX)

(Delayed Data from NSDQ)

$37.66 USD

37.66
184,435

+0.09 (0.24%)

Updated Nov 5, 2024 04:00 PM ET

After-Market: $37.66 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

1-Strong Buy of 5 1        

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value B Growth B Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (89 out of 251)

Industry: Medical - Products

Zacks News

Strength Seen in SurModics (SRDX): Can Its 16.1% Jump Turn into More Strength?

SurModics (SRDX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Surmodics' (SRDX) Receipt of New FDA Nod to Boost Patient Care

Surmodics' (SRDX) receipt of FDA's clearance is expected to expand the treatment range of the Pounce platform and serve a wider patient pool.

Here's Why SurModics (SRDX) Is a Great 'Buy the Bottom' Stock Now

SurModics (SRDX) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.

Down -18.32% in 4 Weeks, Here's Why You Should You Buy the Dip in SurModics (SRDX)

SurModics (SRDX) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Surmodics (SRDX) Q2 Earnings Top Estimates, FY23 View Revised

Surmodics (SRDX) reports a solid fiscal second-quarter top line on the back of robust Medical Device revenues.

SurModics (SRDX) Reports Q2 Loss, Tops Revenue Estimates

SurModics (SRDX) delivered earnings and revenue surprises of 18.37% and 4.63%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Abbott (ABT) Beats Q1 Earnings and Revenue Estimates

Abbott (ABT) delivered earnings and revenue surprises of 5.10% and 1.07%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Here's Why You Should Retain Surmodics (SRDX) Stock for Now

Investors continue to feel optimistic about Surmodics (SRDX) owing to its solid prospects in the thrombectomy business.

Neogen (NEOG) Q3 Earnings Beat Estimates

Neogen (NEOG) delivered earnings and revenue surprises of 200% and 1.60%, respectively, for the quarter ended February 2023. Do the numbers hold clues to what lies ahead for the stock?

Surmodics (SRDX) Gets FDA's Formal Feedback About SurVeil DCB

Surmodics' (SRDX) receipt of the FDA's positive formal feedback regarding its PMA application for the SurVeil DCB looks promising.

SurModics (SRDX) Moves 5.4% Higher: Will This Strength Last?

SurModics (SRDX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.

SurModics (SRDX) Down 37.2% Since Last Earnings Report: Can It Rebound?

SurModics (SRDX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Here's Why You Should Retain Surmodics (SRDX) Stock for Now

Investors continue to be optimistic about Surmodics (SRDX) owing to its solid prospects in the thrombectomy business.

Surmodics (SRDX) Q1 Earnings Top Estimates, FY23 View Revised

Surmodics (SRDX) reports a solid fiscal first quarter top line on the back of robust Medical Device revenues.

SurModics (SRDX) Reports Q1 Loss, Tops Revenue Estimates

SurModics (SRDX) delivered earnings and revenue surprises of 21.88% and 3.09%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Haemonetics (HAE) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Haemonetics (HAE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

High Tide Inc. (HITI) Reports Q4 Loss, Tops Revenue Estimates

High Tide Inc. (HITI) delivered earnings and revenue surprises of -20% and 7.26%, respectively, for the quarter ended October 2022. Do the numbers hold clues to what lies ahead for the stock?

Earnings Preview: SurModics (SRDX) Q1 Earnings Expected to Decline

SurModics (SRDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Abbott (ABT) Q4 Earnings and Revenues Top Estimates

Abbott (ABT) delivered earnings and revenue surprises of 14.44% and 6.47%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

SurModics (SRDX) Surges 6.1%: Is This an Indication of Further Gains?

SurModics (SRDX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Surmodics (SRDX) Stock Skids 32% on Negative Regulatory Update

Surmodics' (SRDX) SurVeil drug-coated balloon candidate receives additional data requests from the FDA.

3 Reasons to Retain Surmodics (SRDX) Stock in Your Portfolio

Investors continue to be optimistic about Surmodics (SRDX) owing to its solid prospects in the thrombectomy business.

Surmodics (SRDX) Q4 Earnings and Revenues Top Estimates

Surmodics (SRDX) reports a solid fiscal fourth quarter top line on the back of robust Medical Device revenues.

SurModics (SRDX) Reports Q4 Loss, Tops Revenue Estimates

SurModics (SRDX) delivered earnings and revenue surprises of 31.58% and 4.64%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

ICU Medical (ICUI) Surpasses Q3 Earnings and Revenue Estimates

ICU Medical (ICUI) delivered earnings and revenue surprises of 24.11% and 6.21%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?